Literature DB >> 34199483

Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma.

Charlotte Rennert1, Catrin Tauber1,2, Pia Fehrenbach1,2, Kathrin Heim1,2, Dominik Bettinger1, Özlem Sogukpinar1, Anita Schuch1,2, Britta Franziska Zecher1,3, Bertram Bengsch1, Sven A Lang4,5, Peter Bronsert6,7, Niklas K Björkström8, Stefan Fichtner-Feigl4, Michael Schultheiss1, Robert Thimme1, Maike Hofmann1.   

Abstract

Hepatocellular carcinoma (HCC) is a global health burden with increasing incidence, poor prognosis and limited therapeutic options. Natural killer (NK) cells exhibit potent anti-tumoral activity and therefore represent potential targets for immunotherapeutic approaches in HCC treatment. However, the anti-tumoral activity of NK cells in HCC associated with different etiologies, and the impact of the heterogeneous NK cell subset, e.g., adaptive and conventional subsets, are not understood in detail. By comparatively analyzing the NK-cell repertoire in 60 HCC patients, 33 liver cirrhosis patients and 36 healthy donors (HD), we show in this study that the NK-cell repertoire is linked to HCC etiology, with increased frequencies of adaptive NK cells in Hepatitis B virus (HBV)-associated HCC. Adaptive NK cells exhibited limited anti-tumoral activity toward liver cancer cells; however, this was not a result of a specific NK-cell impairment in HCC but rather represented an intrinsic feature, since the characteristics of circulating and intra-tumoral adaptive NK cells were conserved between HD, HCC and liver cirrhosis patients. Hence, the expansion of adaptive NK cells with reduced anti-tumoral activity, detectable in HBV-associated HCC, may have implications for tumor surveillance and therapy.

Entities:  

Keywords:  HBV; HCC; HCMV; liver cirrhosis

Year:  2021        PMID: 34199483     DOI: 10.3390/cells10061369

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  3 in total

1.  Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma.

Authors:  Hongjun Xie; Muqi Shi; Yifei Liu; Changhong Cheng; Lining Song; Zihan Ding; Huanzhi Jin; Xiaohong Cui; Yan Wang; Dengfu Yao; Peng Wang; Min Yao; Haijian Zhang
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

2.  T and NK Cell-Based Immunotherapy in Chronic Viral Hepatitis and Hepatocellular Carcinoma.

Authors:  Paola Fisicaro; Carolina Boni
Journal:  Cells       Date:  2022-01-06       Impact factor: 6.600

Review 3.  Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy.

Authors:  Rossella Fasano; Mahdi Abdoli Shadbad; Oronzo Brunetti; Antonella Argentiero; Angela Calabrese; Patrizia Nardulli; Roberto Calbi; Behzad Baradaran; Nicola Silvestris
Journal:  Life (Basel)       Date:  2021-12-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.